APO Research
Talk to an analyst

APO RESEARCH · REPORT

Site-directed Mutagenesis Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Site-directed Mutagenesis Service Market Outlook and Growth Opportunities 2026

12 August 2026216 pages

Choose your research edition.

Industry ResearchSite-directed Mutagenesis Service Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Site-directed Mutagenesis Service Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Site-directed Mutagenesis Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Site-directed Mutagenesis Service Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Site-directed Mutagenesis Service Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Site-directed Mutagenesis Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Site-directed Mutagenesis Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Site-directed Mutagenesis Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Site-directed Mutagenesis Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Site-directed Mutagenesis Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Site-directed Mutagenesis Service market include Azenta Life Sciences, Thermo Fisher Scientific, Bon Opus Biosciences, Charles Rive, Creative Biogene, Synbio Technologies, Creative Biolabs, NovoPro and Bionexus, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Site-directed Mutagenesis Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Site-directed Mutagenesis Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Site-directed Mutagenesis Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Site-directed Mutagenesis Service market.

Site-directed Mutagenesis Service Segment by Company

Azenta Life Sciences

Thermo Fisher Scientific

Bon Opus Biosciences

Charles Rive

Creative Biogene

Synbio Technologies

Creative Biolabs

NovoPro

Bionexus

Biotech Desk

NorClone

Eton Bioscience

Syd Labs

Genosphere Biotechnologies

WZ Biosciences

FulenGen

GENEWIZ

iGene Biotechnology

Tsingke

AtaGenix

Zoonbio Biotechnology

GenScript

Eurofins

Applied Biological Materials

Site-directed Mutagenesis Service Segment by Type

Standard Site-directed Mutagenesis Service

Customized Site-directed Mutagenesis Service

Site-directed Mutagenesis Service Segment by Application

Scientific Research

Gene Therapy

Cell Therapy

Others

Site-directed Mutagenesis Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Site-directed Mutagenesis Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Site-directed Mutagenesis Service key companies, revenue, market share, and recent developments.

3. To split the Site-directed Mutagenesis Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Site-directed Mutagenesis Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Site-directed Mutagenesis Service significant trends, drivers, influence factors in global and regions.

6. To analyze Site-directed Mutagenesis Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Site-directed Mutagenesis Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Site-directed Mutagenesis Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Site-directed Mutagenesis Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Site-directed Mutagenesis Service industry.

Chapter 3: Detailed analysis of Site-directed Mutagenesis Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Site-directed Mutagenesis Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Site-directed Mutagenesis Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Site-directed Mutagenesis Service Industry Trends Table 2. Site-directed Mutagenesis Service Industry Drivers Table 3. Site-directed Mutagenesis Service Industry Opportunities and Challenges Table 4. Site-directed Mutagenesis Service Industry Restraints Table 5. Global Site-directed Mutagenesis Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Site-directed Mutagenesis Service Revenue Share by Company (2021-2026) Table 7. Global Site-directed Mutagenesis Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Site-directed Mutagenesis Service Key Company Manufacturing Base & Headquarters Table 9. Global Site-directed Mutagenesis Service Company, Product Type & Application Table 10. Global Site-directed Mutagenesis Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Site-directed Mutagenesis Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Standard Site-directed Mutagenesis Service Table 15. Significant Companies of Customized Site-directed Mutagenesis Service Table 16. Global Site-directed Mutagenesis Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Site-directed Mutagenesis Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Site-directed Mutagenesis Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Site-directed Mutagenesis Service Sales Value Share by Type (2021-2026) Table 20. Global Site-directed Mutagenesis Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Scientific Research Table 22. Significant Companies of Gene Therapy Table 23. Significant Companies of Cell Therapy Table 24. Significant Companies of Others Table 25. Global Site-directed Mutagenesis Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Site-directed Mutagenesis Service Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Site-directed Mutagenesis Service Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Site-directed Mutagenesis Service Sales Value Share by Application (2021-2026) Table 29. Global Site-directed Mutagenesis Service Sales Value Share by Application (2027-2032) Table 30. Global Site-directed Mutagenesis Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Site-directed Mutagenesis Service Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Site-directed Mutagenesis Service Sales Value Share by Region (2021-2026) Table 33. Global Site-directed Mutagenesis Service Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Site-directed Mutagenesis Service Sales Value Share by Region (2027-2032) Table 35. Global Site-directed Mutagenesis Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Site-directed Mutagenesis Service Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Site-directed Mutagenesis Service Sales Value Market Share by Country (2021-2026) Table 38. Global Site-directed Mutagenesis Service Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Site-directed Mutagenesis Service Sales Value Market Share by Country (2027-2032) Table 40. Azenta Life Sciences Company Information Table 41. Azenta Life Sciences Business Overview Table 42. Azenta Life Sciences Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Azenta Life Sciences Site-directed Mutagenesis Service Product Portfolio Table 44. Azenta Life Sciences Recent Development Table 45. Thermo Fisher Scientific Company Information Table 46. Thermo Fisher Scientific Business Overview Table 47. Thermo Fisher Scientific Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Thermo Fisher Scientific Site-directed Mutagenesis Service Product Portfolio Table 49. Thermo Fisher Scientific Recent Development Table 50. Bon Opus Biosciences Company Information Table 51. Bon Opus Biosciences Business Overview Table 52. Bon Opus Biosciences Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Bon Opus Biosciences Site-directed Mutagenesis Service Product Portfolio Table 54. Bon Opus Biosciences Recent Development Table 55. Charles Rive Company Information Table 56. Charles Rive Business Overview Table 57. Charles Rive Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Charles Rive Site-directed Mutagenesis Service Product Portfolio Table 59. Charles Rive Recent Development Table 60. Creative Biogene Company Information Table 61. Creative Biogene Business Overview Table 62. Creative Biogene Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Creative Biogene Site-directed Mutagenesis Service Product Portfolio Table 64. Creative Biogene Recent Development Table 65. Synbio Technologies Company Information Table 66. Synbio Technologies Business Overview Table 67. Synbio Technologies Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Synbio Technologies Site-directed Mutagenesis Service Product Portfolio Table 69. Synbio Technologies Recent Development Table 70. Creative Biolabs Company Information Table 71. Creative Biolabs Business Overview Table 72. Creative Biolabs Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Creative Biolabs Site-directed Mutagenesis Service Product Portfolio Table 74. Creative Biolabs Recent Development Table 75. NovoPro Company Information Table 76. NovoPro Business Overview Table 77. NovoPro Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. NovoPro Site-directed Mutagenesis Service Product Portfolio Table 79. NovoPro Recent Development Table 80. Bionexus Company Information Table 81. Bionexus Business Overview Table 82. Bionexus Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bionexus Site-directed Mutagenesis Service Product Portfolio Table 84. Bionexus Recent Development Table 85. Biotech Desk Company Information Table 86. Biotech Desk Business Overview Table 87. Biotech Desk Site-directed Mutagenesis Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biotech Desk Site-directed Mutagenesis Service Product Portfolio Table 89. Biotech Desk Recent Development Table 90. NorClone Company Information Table 91. NorClone Business Overview Table 92. NorClone Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. NorClone Site-directed Mutagenesis Service Product Portfolio Table 94. NorClone Recent Development Table 95. Eton Bioscience Company Information Table 96. Eton Bioscience Business Overview Table 97. Eton Bioscience Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Eton Bioscience Site-directed Mutagenesis Service Product Portfolio Table 99. Eton Bioscience Recent Development Table 100. Syd Labs Company Information Table 101. Syd Labs Business Overview Table 102. Syd Labs Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Syd Labs Site-directed Mutagenesis Service Product Portfolio Table 104. Syd Labs Recent Development Table 105. Genosphere Biotechnologies Company Information Table 106. Genosphere Biotechnologies Business Overview Table 107. Genosphere Biotechnologies Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Genosphere Biotechnologies Site-directed Mutagenesis Service Product Portfolio Table 109. Genosphere Biotechnologies Recent Development Table 110. WZ Biosciences Company Information Table 111. WZ Biosciences Business Overview Table 112. WZ Biosciences Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. WZ Biosciences Site-directed Mutagenesis Service Product Portfolio Table 114. WZ Biosciences Recent Development Table 115. FulenGen Company Information Table 116. FulenGen Business Overview Table 117. FulenGen Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. FulenGen Site-directed Mutagenesis Service Product Portfolio Table 119. FulenGen Recent Development Table 120. GENEWIZ Company Information Table 121. GENEWIZ Business Overview Table 122. GENEWIZ Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. GENEWIZ Site-directed Mutagenesis Service Product Portfolio Table 124. GENEWIZ Recent Development Table 125. iGene Biotechnology Company Information Table 126. iGene Biotechnology Business Overview Table 127. iGene Biotechnology Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. iGene Biotechnology Site-directed Mutagenesis Service Product Portfolio Table 129. iGene Biotechnology Recent Development Table 130. Tsingke Company Information Table 131. Tsingke Business Overview Table 132. Tsingke Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. Tsingke Site-directed Mutagenesis Service Product Portfolio Table 134. Tsingke Recent Development Table 135. AtaGenix Company Information Table 136. AtaGenix Business Overview Table 137. AtaGenix Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. AtaGenix Site-directed Mutagenesis Service Product Portfolio Table 139. AtaGenix Recent Development Table 140. Zoonbio Biotechnology Company Information Table 141. Zoonbio Biotechnology Business Overview Table 142. Zoonbio Biotechnology Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 143. Zoonbio Biotechnology Site-directed Mutagenesis Service Product Portfolio Table 144. Zoonbio Biotechnology Recent Development Table 145. GenScript Company Information Table 146. GenScript Business Overview Table 147. GenScript Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 148. GenScript Site-directed Mutagenesis Service Product Portfolio Table 149. GenScript Recent Development Table 150. Eurofins Company Information Table 151. Eurofins Business Overview Table 152. Eurofins Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 153. Eurofins Site-directed Mutagenesis Service Product Portfolio Table 154. Eurofins Recent Development Table 155. Applied Biological Materials Company Information Table 156. Applied Biological Materials Business Overview Table 157. Applied Biological Materials Site-directed Mutagenesis Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 158. Applied Biological Materials Site-directed Mutagenesis Service Product Portfolio Table 159. Applied Biological Materials Recent Development Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Site-directed Mutagenesis Service Product Image Figure 2. Global Site-directed Mutagenesis Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Site-directed Mutagenesis Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Site-directed Mutagenesis Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Standard Site-directed Mutagenesis Service Image Figure 8. Customized Site-directed Mutagenesis Service Image Figure 9. Global Site-directed Mutagenesis Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Site-directed Mutagenesis Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Site-directed Mutagenesis Service Sales Value Share by Type (2021-2032) Figure 12. Scientific Research Image Figure 13. Gene Therapy Image Figure 14. Cell Therapy Image Figure 15. Others Image Figure 16. Global Site-directed Mutagenesis Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Site-directed Mutagenesis Service Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Site-directed Mutagenesis Service Sales Value Share by Application (2021-2032) Figure 19. Global Site-directed Mutagenesis Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Site-directed Mutagenesis Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Site-directed Mutagenesis Service Sales Value (2021-2032) & (US$ Million) Figure 22. North America Site-directed Mutagenesis Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Site-directed Mutagenesis Service Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Site-directed Mutagenesis Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Site-directed Mutagenesis Service Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Site-directed Mutagenesis Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Site-directed Mutagenesis Service Sales Value (2021-2032) & (US$ Million) Figure 28. South America Site-directed Mutagenesis Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Site-directed Mutagenesis Service Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Site-directed Mutagenesis Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Standard Site-directed Mutagenesis Service
  • Customized Site-directed Mutagenesis Service
Applications
  • Scientific Research
  • Gene Therapy
  • Cell Therapy
  • Others
Companies covered
  • Azenta Life Sciences
  • Thermo Fisher Scientific
  • Bon Opus Biosciences
  • Charles Rive
  • Creative Biogene
  • Synbio Technologies
  • Creative Biolabs
  • NovoPro
  • Bionexus
  • Biotech Desk
  • NorClone
  • Eton Bioscience
  • Syd Labs
  • Genosphere Biotechnologies
  • WZ Biosciences
  • FulenGen
  • GENEWIZ
  • iGene Biotechnology
  • Tsingke
  • AtaGenix
  • Zoonbio Biotechnology
  • GenScript
  • Eurofins
  • Applied Biological Materials

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Site-directed Mutagenesis Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Site-directed Mutagenesis Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Site-directed Mutagenesis Service Market Dynamics
  1. 2.1 Site-directed Mutagenesis Service Industry Trends
  2. 2.2 Site-directed Mutagenesis Service Industry Drivers
  3. 2.3 Site-directed Mutagenesis Service Industry Opportunities and Challenges
  4. 2.4 Site-directed Mutagenesis Service Industry Restraints
3 Site-directed Mutagenesis Service Market by Company
  1. 3.1 Global Site-directed Mutagenesis Service Company Revenue Ranking in 2025
  2. 3.2 Global Site-directed Mutagenesis Service Revenue by Company (2021-2026)
  3. 3.3 Global Site-directed Mutagenesis Service Company Ranking (2024-2026)
  4. 3.4 Global Site-directed Mutagenesis Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Site-directed Mutagenesis Service Company Product Type and Application
  6. 3.6 Global Site-directed Mutagenesis Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Site-directed Mutagenesis Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Site-directed Mutagenesis Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Site-directed Mutagenesis Service Market by Type
  1. 4.1 Site-directed Mutagenesis Service Type Introduction
  2. 4.1.1 Standard Site-directed Mutagenesis Service
  3. 4.1.2 Customized Site-directed Mutagenesis Service
  4. 4.2 Global Site-directed Mutagenesis Service Sales Value by Type
  5. 4.2.1 Global Site-directed Mutagenesis Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Site-directed Mutagenesis Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global Site-directed Mutagenesis Service Sales Value Share by Type (2021-2032)
5 Site-directed Mutagenesis Service Market by Application
  1. 5.1 Site-directed Mutagenesis Service Application Introduction
  2. 5.1.1 Scientific Research
  3. 5.1.2 Gene Therapy
  4. 5.1.3 Cell Therapy
  5. 5.1.4 Others
  6. 5.2 Global Site-directed Mutagenesis Service Sales Value by Application
  7. 5.2.1 Global Site-directed Mutagenesis Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Site-directed Mutagenesis Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Site-directed Mutagenesis Service Sales Value Share by Application (2021-2032)
6 Site-directed Mutagenesis Service Regional Value Analysis
  1. 6.1 Global Site-directed Mutagenesis Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Site-directed Mutagenesis Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Site-directed Mutagenesis Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Site-directed Mutagenesis Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Site-directed Mutagenesis Service Sales Value (2021-2032)
  7. 6.3.2 North America Site-directed Mutagenesis Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Site-directed Mutagenesis Service Sales Value (2021-2032)
  10. 6.4.2 Europe Site-directed Mutagenesis Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Site-directed Mutagenesis Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Site-directed Mutagenesis Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Site-directed Mutagenesis Service Sales Value (2021-2032)
  16. 6.6.2 South America Site-directed Mutagenesis Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Site-directed Mutagenesis Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Site-directed Mutagenesis Service Sales Value Share by Country, 2025 VS 2032
7 Site-directed Mutagenesis Service Country-level Value Analysis
  1. 7.1 Global Site-directed Mutagenesis Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Site-directed Mutagenesis Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Site-directed Mutagenesis Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Site-directed Mutagenesis Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Site-directed Mutagenesis Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Site-directed Mutagenesis Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Site-directed Mutagenesis Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Azenta Life Sciences
  2. 8.1.1 Azenta Life Sciences Company Information
  3. 8.1.2 Azenta Life Sciences Business Overview
  4. 8.1.3 Azenta Life Sciences Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Azenta Life Sciences Site-directed Mutagenesis Service Product Portfolio
  6. 8.1.5 Azenta Life Sciences Recent Developments
  7. 8.2 Thermo Fisher Scientific
  8. 8.2.1 Thermo Fisher Scientific Company Information
  9. 8.2.2 Thermo Fisher Scientific Business Overview
  10. 8.2.3 Thermo Fisher Scientific Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Thermo Fisher Scientific Site-directed Mutagenesis Service Product Portfolio
  12. 8.2.5 Thermo Fisher Scientific Recent Developments
  13. 8.3 Bon Opus Biosciences
  14. 8.3.1 Bon Opus Biosciences Company Information
  15. 8.3.2 Bon Opus Biosciences Business Overview
  16. 8.3.3 Bon Opus Biosciences Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bon Opus Biosciences Site-directed Mutagenesis Service Product Portfolio
  18. 8.3.5 Bon Opus Biosciences Recent Developments
  19. 8.4 Charles Rive
  20. 8.4.1 Charles Rive Company Information
  21. 8.4.2 Charles Rive Business Overview
  22. 8.4.3 Charles Rive Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles Rive Site-directed Mutagenesis Service Product Portfolio
  24. 8.4.5 Charles Rive Recent Developments
  25. 8.5 Creative Biogene
  26. 8.5.1 Creative Biogene Company Information
  27. 8.5.2 Creative Biogene Business Overview
  28. 8.5.3 Creative Biogene Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Creative Biogene Site-directed Mutagenesis Service Product Portfolio
  30. 8.5.5 Creative Biogene Recent Developments
  31. 8.6 Synbio Technologies
  32. 8.6.1 Synbio Technologies Company Information
  33. 8.6.2 Synbio Technologies Business Overview
  34. 8.6.3 Synbio Technologies Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Synbio Technologies Site-directed Mutagenesis Service Product Portfolio
  36. 8.6.5 Synbio Technologies Recent Developments
  37. 8.7 Creative Biolabs
  38. 8.7.1 Creative Biolabs Company Information
  39. 8.7.2 Creative Biolabs Business Overview
  40. 8.7.3 Creative Biolabs Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Creative Biolabs Site-directed Mutagenesis Service Product Portfolio
  42. 8.7.5 Creative Biolabs Recent Developments
  43. 8.8 NovoPro
  44. 8.8.1 NovoPro Company Information
  45. 8.8.2 NovoPro Business Overview
  46. 8.8.3 NovoPro Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NovoPro Site-directed Mutagenesis Service Product Portfolio
  48. 8.8.5 NovoPro Recent Developments
  49. 8.9 Bionexus
  50. 8.9.1 Bionexus Company Information
  51. 8.9.2 Bionexus Business Overview
  52. 8.9.3 Bionexus Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bionexus Site-directed Mutagenesis Service Product Portfolio
  54. 8.9.5 Bionexus Recent Developments
  55. 8.10 Biotech Desk
  56. 8.10.1 Biotech Desk Company Information
  57. 8.10.2 Biotech Desk Business Overview
  58. 8.10.3 Biotech Desk Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biotech Desk Site-directed Mutagenesis Service Product Portfolio
  60. 8.10.5 Biotech Desk Recent Developments
  61. 8.11 NorClone
  62. 8.11.1 NorClone Company Information
  63. 8.11.2 NorClone Business Overview
  64. 8.11.3 NorClone Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NorClone Site-directed Mutagenesis Service Product Portfolio
  66. 8.11.5 NorClone Recent Developments
  67. 8.12 Eton Bioscience
  68. 8.12.1 Eton Bioscience Company Information
  69. 8.12.2 Eton Bioscience Business Overview
  70. 8.12.3 Eton Bioscience Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eton Bioscience Site-directed Mutagenesis Service Product Portfolio
  72. 8.12.5 Eton Bioscience Recent Developments
  73. 8.13 Syd Labs
  74. 8.13.1 Syd Labs Company Information
  75. 8.13.2 Syd Labs Business Overview
  76. 8.13.3 Syd Labs Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Syd Labs Site-directed Mutagenesis Service Product Portfolio
  78. 8.13.5 Syd Labs Recent Developments
  79. 8.14 Genosphere Biotechnologies
  80. 8.14.1 Genosphere Biotechnologies Company Information
  81. 8.14.2 Genosphere Biotechnologies Business Overview
  82. 8.14.3 Genosphere Biotechnologies Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Genosphere Biotechnologies Site-directed Mutagenesis Service Product Portfolio
  84. 8.14.5 Genosphere Biotechnologies Recent Developments
  85. 8.15 WZ Biosciences
  86. 8.15.1 WZ Biosciences Company Information
  87. 8.15.2 WZ Biosciences Business Overview
  88. 8.15.3 WZ Biosciences Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 WZ Biosciences Site-directed Mutagenesis Service Product Portfolio
  90. 8.15.5 WZ Biosciences Recent Developments
  91. 8.16 FulenGen
  92. 8.16.1 FulenGen Company Information
  93. 8.16.2 FulenGen Business Overview
  94. 8.16.3 FulenGen Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 FulenGen Site-directed Mutagenesis Service Product Portfolio
  96. 8.16.5 FulenGen Recent Developments
  97. 8.17 GENEWIZ
  98. 8.17.1 GENEWIZ Company Information
  99. 8.17.2 GENEWIZ Business Overview
  100. 8.17.3 GENEWIZ Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 GENEWIZ Site-directed Mutagenesis Service Product Portfolio
  102. 8.17.5 GENEWIZ Recent Developments
  103. 8.18 iGene Biotechnology
  104. 8.18.1 iGene Biotechnology Company Information
  105. 8.18.2 iGene Biotechnology Business Overview
  106. 8.18.3 iGene Biotechnology Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 iGene Biotechnology Site-directed Mutagenesis Service Product Portfolio
  108. 8.18.5 iGene Biotechnology Recent Developments
  109. 8.19 Tsingke
  110. 8.19.1 Tsingke Company Information
  111. 8.19.2 Tsingke Business Overview
  112. 8.19.3 Tsingke Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Tsingke Site-directed Mutagenesis Service Product Portfolio
  114. 8.19.5 Tsingke Recent Developments
  115. 8.20 AtaGenix
  116. 8.20.1 AtaGenix Company Information
  117. 8.20.2 AtaGenix Business Overview
  118. 8.20.3 AtaGenix Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  119. 8.20.4 AtaGenix Site-directed Mutagenesis Service Product Portfolio
  120. 8.20.5 AtaGenix Recent Developments
  121. 8.21 Zoonbio Biotechnology
  122. 8.21.1 Zoonbio Biotechnology Company Information
  123. 8.21.2 Zoonbio Biotechnology Business Overview
  124. 8.21.3 Zoonbio Biotechnology Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Zoonbio Biotechnology Site-directed Mutagenesis Service Product Portfolio
  126. 8.21.5 Zoonbio Biotechnology Recent Developments
  127. 8.22 GenScript
  128. 8.22.1 GenScript Company Information
  129. 8.22.2 GenScript Business Overview
  130. 8.22.3 GenScript Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  131. 8.22.4 GenScript Site-directed Mutagenesis Service Product Portfolio
  132. 8.22.5 GenScript Recent Developments
  133. 8.23 Eurofins
  134. 8.23.1 Eurofins Company Information
  135. 8.23.2 Eurofins Business Overview
  136. 8.23.3 Eurofins Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Eurofins Site-directed Mutagenesis Service Product Portfolio
  138. 8.23.5 Eurofins Recent Developments
  139. 8.24 Applied Biological Materials
  140. 8.24.1 Applied Biological Materials Company Information
  141. 8.24.2 Applied Biological Materials Business Overview
  142. 8.24.3 Applied Biological Materials Site-directed Mutagenesis Service Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Applied Biological Materials Site-directed Mutagenesis Service Product Portfolio
  144. 8.24.5 Applied Biological Materials Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst